ADVERTISEMENT

Robert Chen

PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma

Background: Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma originating from germinal-center B cells.

Leonie Gordon , MD;

Nathan Fowler ;

10/19/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8

NEI Congress

November 7 ⁠–⁠ November 10

WoundCon

November 8

November 8 ⁠–⁠ November 10

Dermatology Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Advertisement

Advertisement